The Effects of Aripiprazole on Electrocardiography in Children with Pervasive Developmental Disorders

Ho, Jason G.; Caldwell, Randall L.; McDougle, Christopher J.; Orsagh-Yentis, Danielle; Erickson, Craig A.; Posey, David J.; Stigler, Kimberly A.

doi:10.1089/cap.2011.0129

Cited by 21 publications

(16 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 36 , 37 , 86 One prospective, open-label study (n=25; age range: 5–17 years) investigated aripiprazole use for treating irritability in cases of Asperger’s disorder and pervasive developmental disorder not otherwise specified, and found no significant changes in the PR, QRS, RR, and QTc intervals after 14 weeks of aripiprazole therapy. 88 The posttreatment QTc values were all below 440 ms, and the administered dosage was not significantly correlated with the percent change in QTc. 88 These results suggest that aripiprazole does not significantly impact cardiac health and carries a low risk of causing sudden death.…”

Section: Aripiprazole Safety Data In Children and Adolescentsmentioning

confidence: 85%

See 1 more Smart Citation

Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

Kirino

2014

AHMT

View full text Add to dashboard Cite

Bipolar disorder is a pernicious illness. Compared with the later-onset form, early onset bipolar disorder is associated with worse psychosocial outcomes, and is characterized by rapid cycling and increased risks of substance abuse and suicide attempts. Controlling mood episodes and preventing relapse in this group of pediatric patients requires careful treatment. Here, we review the effectiveness of aripiprazole for bipolar disorder in children and adolescents, with discussion of this drug’s unique pharmacological profile and various clinical study outcomes. Aripiprazole acts as a serotonin 5-HT2A receptor antagonist, as well as a partial agonist of the serotonin 5-HT1A and dopamine D2 receptors. It can be safely used in children and adolescents, as it is highly tolerated and shows lower rates of the side effects typically observed with other antipsychotic drugs, including sedation, weight gain, hyperprolactinemia, and extrapyramidal syndrome. The presently reviewed randomized controlled trials (RCTs) and non-RCTs generally reported aripiprazole to be effective and well-tolerated in children and adolescents with bipolar disorder. However, due to the limited number of RCTs, the present conclusions must be evaluated cautiously. Furthermore, aripiprazole cannot yet be considered a preferred treatment for children and adolescents with bipolar disorder, as there is not yet evidence that aripiprazole shows greater efficacy compared to other second-generation antipsychotics. Additional data are needed from future head-to-head comparison studies.

show abstract

Section: Aripiprazole Safety Data In Children and Adolescentsmentioning

confidence: 85%

“… 88 The posttreatment QTc values were all below 440 ms, and the administered dosage was not significantly correlated with the percent change in QTc. 88 These results suggest that aripiprazole does not significantly impact cardiac health and carries a low risk of causing sudden death.…”

Section: Aripiprazole Safety Data In Children and Adolescentsmentioning

confidence: 85%

Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

Kirino

2014

AHMT

View full text Add to dashboard Cite

show abstract

“…Furthermore, the QTc interval showed a significant shortening after switching from OLZ to ARP (Suzuki et al ., ). In children with pervasive development disorders, ARP treatment did not change the QTc interval (Ho et al ., ). Our results are consistent with those of the three studies.…”

Section: Discussionmentioning

confidence: 97%

Sex differences in the effect of four second‐generation antipsychotics on QTc interval in patients with schizophrenia

Suzuki

Sugai

Fukui

et al. 2013

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Aripiprazole has not been associated with significant QTc interval prolongation or other abnormal ECG findings in children with ASD. 111 Other atypical antipsychotics have not been as thoroughly investigated in children with autism, and the studies have typically yielded mixed results. Two small open-label trials of olanzapine reported high response rates (6/7 and 5/6 participants), 112,113 though results from an additional two studies were less robust (3/25 participants and 12/40 participants were responders).…”

Section: Atypical Antipsychoticsmentioning

confidence: 99%

Psychopharmacological Interventions in Autism Spectrum Disorder

Politte

Henry

McDougle

2014

Harvard Review of Psychiatry

Self Cite

View full text Add to dashboard Cite

After participating in this educational activity, the physician should be better able to1. Prescribe the appropriate psychotropic medication to treat symptoms of ASD.2. Identify the side effects of the psychotropic medications used to treat ASD.Autism spectrum disorders (ASDs) are characterized by core deficits in social communication and language, and restrictive and repetitive behaviors that cause significant functional impairment and distress for affected individuals and their caregivers. The increasing prevalence of ASD, most recently estimated as 1 in 88 children, presents an ever-increasing burden on families, schools, medical systems, and society at large. Individuals with ASD commonly present for treatment of associated emotional and behavioral disturbances that include anxiety, symptoms of ADHD, compulsions and other repetitive behaviors, mood lability, irritability, aggression, and sleep disturbance. Psychotropic medications are widely utilized in alleviating these symptoms, though rigorous clinical trials in ASD are lacking for most areas of impairment. Strong evidence from randomized, placebo-controlled trials supports the use of atypical antipsychotics, particularly risperidone and aripiprazole, for managing severe irritability and aggression in ASD. Serotonin reuptake inhibitors are commonly used to treat anxiety and compulsions, though reports of efficacy in the literature are mixed, and behavioral side effects in children are common. Minimal evidence supports the utility of anticonvulsants and traditional mood stabilizers in managing mood lability and aggression. Stimulant and nonstimulant ADHD medications can be effective for reducing hyperactivity, inattention, and impulsivity, though to a lesser degree than in ADHD populations without ASD and with greater risk of adverse effects. Psychopharmacological interventions in development for core symptoms of autism include those that target the glutamatergic and GABAergic neurotransmitter systems and the neuropeptide oxytocin. Further research is needed to establish evidence-based interventions in ASD populations.

show abstract

The Effects of Aripiprazole on Electrocardiography in Children with Pervasive Developmental Disorders

Cited by 21 publications

References 46 publications

Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

Sex differences in the effect of four second‐generation antipsychotics on QTc interval in patients with schizophrenia

Psychopharmacological Interventions in Autism Spectrum Disorder

Contact Info

Product

Resources

About